Supernus Pharmaceuticals falls as investors weigh newly announced Indivior merger terms

Supernus Pharmaceuticals (SUPN) is down 6.0% today. Here is some analysis on what might have caused this price movement.

Analysis: The most likely catalyst is the market’s reaction to the newly announced all-stock merger with Indivior. While the deal would create a larger CNS-focused drug company, the terms appear to have raised concerns about integration risk, valuation, and how the exchange structure redistributes value between the two shareholder bases.

Details:

Supernus and Indivior announced a merger of equals that would combine their neuroscience and addiction-treatment portfolios into a larger biopharmaceutical company.

The transaction includes stock consideration for Supernus holders, while Indivior holders are set to receive a large special dividend before closing, which may have influenced how investors assessed the economics of the deal.

The companies highlighted expected scale benefits, including roughly $2.2 billion in combined revenue and targeted cost synergies, but investors often discount those benefits until execution looks more certain.

Supernus was also scheduled to report second-quarter 2026 financial results after the market close on August 4, 2026, which may have added caution and short-term volatility.

Sources:

SEC, Supernus Pharmaceuticals, Indivior Pharmaceuticals

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

$SUPN Insider Trading Activity

$SUPN insiders have traded $SUPN stock on the open market 17 times in the past 6 months. Of those trades, 0 have been purchases and 17 have been sales.

Here’s a breakdown of recent trading of $SUPN stock by insiders over the last 6 months:

PADMANABH P. BHATT (Sr. VP of IP, CSO) has made 0 purchases and 6 sales selling 107,250 shares for an estimated $5,388,431.
JACK A. KHATTAR (President, CEO) has made 0 purchases and 3 sales selling 35,000 shares for an estimated $1,763,124.
GEORGES GEMAYEL has made 0 purchases and 2 sales selling 18,787 shares for an estimated $1,002,811.
WILLIAM TODD HORICH (SVP, Commercial Operations) has made 0 purchases and 2 sales selling 8,877 shares for an estimated $483,797.
FREDERICK M. HUDSON sold 5,369 shares for an estimated $271,725
BETHANY SENSENIG has made 0 purchases and 2 sales selling 4,475 shares for an estimated $228,264.
FRANK MOTTOLA (SVP, Chief Tech. Ops. Officer) sold 1,623 shares for an estimated $87,073

To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.

$SUPN Hedge Fund Activity

We have seen 141 institutional investors add shares of $SUPN stock to their portfolio, and 146 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

CITADEL ADVISORS LLC added 1,040,487 shares (+229.7%) to their portfolio in Q1 2026, for an estimated $53,782,773
POINT72 ASSET MANAGEMENT, L.P. removed 946,245 shares (-41.8%) from their portfolio in Q1 2026, for an estimated $48,911,404
ARMISTICE CAPITAL, LLC removed 868,653 shares (-31.4%) from their portfolio in Q1 2026, for an estimated $44,900,673
MILLENNIUM MANAGEMENT LLC added 675,907 shares (+25.6%) to their portfolio in Q1 2026, for an estimated $34,937,632
ASSENAGON ASSET MANAGEMENT S.A. removed 457,443 shares (-86.2%) from their portfolio in Q2 2026, for an estimated $21,275,673
WOODLINE PARTNERS LP added 448,996 shares (+inf%) to their portfolio in Q1 2026, for an estimated $23,208,603
FREESTONE GROVE PARTNERS LP added 445,001 shares (+226.7%) to their portfolio in Q1 2026, for an estimated $23,002,101

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.

$SUPN Congressional Stock Trading

Members of Congress have traded $SUPN stock 1 times in the past 6 months. Of those trades, 1 have been purchases and 0 have been sales.

Here’s a breakdown of recent trading of $SUPN stock by members of Congress over the last 6 months:

REPRESENTATIVE GILBERT RAY CISNEROS, JR. purchased up to $15,000 on 03/03.

To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard. You can access data on congressional stock trades through the Quiver Quantitative API Congress trades endpoint.

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.